INVO Bioscience announced the company received notice from The Nasdaq Capital Market, dated November 22, informing INVO that it has regained compliance with the minimum stockholders’ equity requirement as set forth under NASDAQ Listing Rule 5550(b)(1) for continued listing on Nasdaq. The company will be subject to a mandatory panel monitor for a period of one year from the date of the notification.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on INVO:
- INVO Reports Record Third Quarter 2023 Financial Results
- INVO Earnings this Week: How Will it Perform?
- NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger
- INVO Bioscience solicits waivers from warrant holders
- Free Registration Is Now Open For Tribe Public’s CEO and Q&A Presentation Webinar Event “Accelerating Biotech Value Creation” Featuring NAYA Biosciences CEO Dr. Daniel Teper On Tuesday, October 31, 2023
